bendamustine hydrochloride has been researched along with fluorodeoxyglucose f18 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishizawa, K; Ogura, M; Tateishi, U; Tatsumi, M; Terauchi, T; Tobinai, K | 1 |
| Ando, K; Kim, WS; Niitsu, N; Ogura, M; Suh, C; Tateishi, U; Tatsumi, M; Terauchi, T; Tobinai, K | 1 |
| Czuczman, MS; Graf, DA; Lamonica, D; Munteanu, MC | 1 |
| Choi, HJ; Jo, JC; Lee, YJ; Park, SH; Seo, M | 1 |
3 trial(s) available for bendamustine hydrochloride and fluorodeoxyglucose f18
| Article | Year |
|---|---|
Relevance of monitoring metabolic reduction in patients with relapsed or refractory follicular and mantle cell lymphoma receiving bendamustine: a multicenter study.
Topics: Adult; Aged; Antineoplastic Agents; Bendamustine Hydrochloride; Clinical Trials, Phase II as Topic; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Positron-Emission Tomography; Radiopharmaceuticals; ROC Curve | 2011 |
Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Rituximab; Tomography, X-Ray Computed; Tumor Burden; Young Adult | 2015 |
18F-FDG PET for Measurement of Response and Prediction of Outcome to Relapsed or Refractory Mantle Cell Lymphoma Therapy with Bendamustine-Rituximab.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Drug Monitoring; Female; Fluorodeoxyglucose F18; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Recurrence; Reproducibility of Results; Rituximab; Sensitivity and Specificity; Survival Rate; Treatment Outcome | 2017 |
1 other study(ies) available for bendamustine hydrochloride and fluorodeoxyglucose f18
| Article | Year |
|---|---|
A Case of Adenomyosis Showing Size Reduction in a Follicular Lymphoma Patient Receiving Chemotherapy With R-Bendamustine.
Topics: Adenomyosis; Bendamustine Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lymphoma, Follicular; Middle Aged; Positron Emission Tomography Computed Tomography | 2023 |